Summary of Bill S 1141
The HALT Fentanyl Act, also known as Bill 118 s 1141, is a piece of legislation currently being considered by the US Congress. The purpose of this bill is to address the growing crisis of fentanyl-related deaths in the United States. Fentanyl is a powerful synthetic opioid that is significantly more potent than other opioids, such as heroin or morphine, and has been responsible for a large number of overdose deaths in recent years.
The HALT Fentanyl Act aims to combat the spread of fentanyl by increasing penalties for the production, distribution, and trafficking of the drug. The bill proposes harsher punishments for individuals caught manufacturing or selling fentanyl, with the goal of deterring people from engaging in these illegal activities. Additionally, the legislation seeks to provide law enforcement agencies with more resources to crack down on fentanyl trafficking networks and prevent the drug from entering the country.
In addition to increasing penalties for fentanyl-related crimes, the HALT Fentanyl Act also includes provisions aimed at improving access to treatment for individuals struggling with opioid addiction. The bill allocates funding for programs that provide support and resources to those affected by fentanyl abuse, with the goal of reducing overdose deaths and helping people recover from addiction.
Overall, the HALT Fentanyl Act is a comprehensive piece of legislation that seeks to address the fentanyl crisis from multiple angles. By increasing penalties for fentanyl-related crimes, providing resources for law enforcement efforts, and expanding access to treatment for addiction, this bill aims to combat the spread of fentanyl and save lives in the United States.
Congressional Summary of S 1141
Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act
This bill places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.
Additionally, the bill establishes a new, alternative registration process for schedule I research that is funded by the Department of Health and Human Services or the Department of Veterans Affairs or that is conducted under an investigative new drug exemption from the Food and Drug Administration.
The bill also makes several other changes to registration requirements for conducting research with controlled substances, including
- permitting a single registration for related research sites in certain circumstances,
- waiving the requirement for a new inspection in certain situations, and
- allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.